In this episode of Molecule to Market, you’ll go inside the global drug development and GMP Manufacturing space with David Staunton, Head of Life Sciences Transformation at Cognizant.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Why being a supplier is harder if you have not been on the client side
• An industry driven by change and the importance of digital strategy to drive business outcomes
• Why pharma companies need to be both big and fast to win
• How AI is accelerating promising molecules and leading to GMP Manufacturing and supply bottlenecks
• The future of deployable, modular factories to service population centers that provide better access to personalized medicines
• How generative AI is impacting the industry right now, and how will this evolve with the introduction of robots (or ‘cobots’)

David leads transformation and generative AI, collaborating closely with tier 1 pharma and biotech client teams worldwide. Over the last 25+ years, David has established and directed international teams, pioneering practical, proven, and innovative programs that revolutionize new product introduction (NPI) and GMP manufacturing & supply.

In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs, and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognized speaker on Industry 4.0 and has given lectures on various UCD Master’s Programmes.

LinkedIn: (6) David Staunton | LinkedIn

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Tom Willson, Vice President of Contract Manufacturing at Pfizer CentreOne
• Hanna Lesch, Chief Technology Officer at Exothera
• Stephen Grant, entrepreneurial advisor and angel investor

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, Hanna, and Stephen, covering:

• Unraveling the potential seismic shift in the pharmaceutical outsourcing industry; the BIOSECURE Act and its implications
• Will the BIOSECURE Act accelerate a trend toward a more regionalized approach to drug development and manufacturing?
• How Biotechs/CDMOs are going to adapt their strategies post BIOSECURE Act
• What impacts BIOSECURE will have on the supply chain

The BIOSECURE Act has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the US government. Our guests provide insightful perspectives on the potential implications of this legislation on the supply chain of life-saving drugs across America.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mihaela Simianu, Vice President of R&D and Operations at Singota Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mihaela, covering:

• How having physician parents in Romania motivated Mihaela into a career in the biopharmaceutical space
• What 17 years at Eli Lilly taught her about drug development and commercialization... and why she ultimately left for Amgen
• Why, after 25 years on the drug sponsor-side, she opted to move onto the CDMO side
• The rapid, complex, and fascinating experience of being part of a small CDMO that supports multiple sponsors to serve patients
• The advisory and execution role of a CDMO partner

Dr. Simianu is a transformational leader in the biopharmaceutical industry, renowned for advancing technology and therapeutic products to enhance personalized medicine and public health. She has achieved significant outcomes for multi-billion-dollar organizations, leading to the approval of 20+ new therapeutic agents and the introduction of commercial processes at more than thirty manufacturing sites globally across her tenure with Eli Lilly, Amgen, and Merck.

Her expertise spans multiple disease areas, and she excels in integrating raw material suppliers, facilities, and engineering equipment into pharmaceutical systems. Specializing in modern product development, quality, and manufacturing systems, she has played a pivotal role in injectable drug commercialization and market expansion. She advanced a portfolio of over thirty-five new pipeline products.

Dr. Simianu holds a Ph.D. in Chemistry from Marquette University, an M.S./B.S. in Chemical Engineering from the Babes-Bolyai University of Cluj-Napoca, and a Jack Welch Management Institute certification. She is a recognized international industry expert and has actively volunteered for the Parenteral Drug Association for over 20 years.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.